Press Releases | BioLineRx

Date	Title	Additional Formats
06 May 2024	BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	PDF Version
17 Apr 2024	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	PDF Version
10 Apr 2024	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	PDF Version
01 Apr 2024	BioLineRx Announces $6 Million Registered Direct Offering	PDF Version
26 Mar 2024	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
20 Mar 2024	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	PDF Version
04 Mar 2024	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	PDF Version
28 Feb 2024	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)	PDF Version
16 Feb 2024	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	PDF Version